Late-Presenting Fulminant Immune Checkpoint Inhibitor Myocarditis Managed With Abatacept and Venoarterial Extracorporeal Oxygenation Authors: Daniel S. Kikuchi, Edan Zitelny, Ashish Correa, Jonathan L. Halperin, Evan Leibner, Gregory W. Serrao, Gagan Sahni Published: 2026 ABSTRACT BackgroundImmune checkpoint inhibitor (ICI) myocarditis is an uncommon but potentially fatal cardiovascular immune-related adverse event that typically presents early after initiating immunotherapy.Case SummaryA 36-year-old man with colorectal cancer treated with pembrolizumab presented with cardiogenic shock after 460 days of immunotherapy. Ultimately, he was found to have ICI myocarditis by clinical and histopathological criteria. Despite high-dose corticosteroids, he developed refractory hemodynamic and electrical instability requiring venoarterial extracorporeal membrane oxygenation, abatacept, and therapeutic plasma exchange, with successful recovery of ventricular function and resolution of conduction abnormalities.DiscussionThis case illustrates an unusually late, biopsy-confirmed, fulminant presentation of pembrolizumab-associated myocarditis and highlights the importance of maintaining suspicion for immune-related cardiotoxicity even late during immunotherapy. Early recognition and prompt immunosuppression combined with mechanical circulatory support may be lifesaving in such fulminant cases.Take-Home MessageEarly recognition, aggressive immunosuppression, and hemodynamic support are central to the management of ICI myocarditis. History of Presentation A 36-year-old man initially presented to an outside hospital with altered mental status. Earlier that day he had felt drowsy, which he attributed to hypoglycemia, but when he did not improve with juice his mother called emergency medical services. At the outside hospital, he was found to be bradycardic and hypotensive. He subsequently experienced cardiac arrest, and advanced cardiac life support was performed with rapid return of spontaneous circulation. He was then transferred to our center for further evaluation and management. Past Medical History The patient's medical history is notable for Lynch syndrome [MLH1 c.199G>A (pGly67Arg)], an autosomal-dominant condition that results in mutations in DNA mismatch repair genes and predisposes to cancer. Twenty-two months before presentation, he was diagnosed with left-sided colon adenocarcinoma and underwent left hemicolectomy. He was subsequently treated with adjuvant FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) therapy. Transthoracic echocardiography (TTE) performed 1 month after starting FOLFOX revealed a reduced left ventricular ejection fraction (LVEF) of 25% with global left ventricular hypokinesis and an impaired global longitudinal strain (GLS) of −12.2% (Table 1). Stress cardiomyopathy secondary to 5-fluorouracil cardiotoxicity was suspected given the diffuse nature of the left ventricular hypokinesis, however work-up for his cardiomyopathy, including genetic testing, ischemic evaluation, and cardiac magnetic resonance, was not completed. FOLFOX was discontinued, and guideline-directed medical therapy with metoprolol succinate, losartan, and empagliflozin was initiated. TTE 1 month later showed improvement in his LVEF and GLS to 45% and −16.4%, respectively (Table 1). Sixteen months before presentation, he was found to have recurrent metastatic disease presenting as fluorodeoxyglucose-avid peritoneal nodule on positron emission tomography. He was then initiated on immunotherapy with pembrolizumab. TTE 1 month after starting immunotherapy revealed an LVEF of 50% and GLS of −14.7%. Subsequent surveillance TTEs (Table 1) demonstrated stable LVEF and GLS parameters after completing 22 of the planned 25 cycles of pembrolizumab before his cardiac arrest.Table 1Left Ventricular Ejection Fraction, Global Longitudinal Strain, and Cancer ManagementTime Before PresentationCancer CourseLVEF (%)GLS (%)22 monthsColorectal cancer diagnosis and left hemicolectomy——20 monthsFOLFOX therapy initiated——19 monthsFOLFOX therapy held, started on metoprolol succinate, losartan, empagliflozin25−12.218 monthsNot on any cancer-directed therapy45−16.416 monthsFDG-avid peritoneal nodule identified on PET——15 monthsPembrolizumab therapy initiated——14 monthsPembrolizumab therapy ongoing40−14.97 monthsPembrolizumab therapy ongoing50−14.71 monthPembrolizumab therapy ongoing60−17.60.5 monthFinal pembrolizumab dose prior to presentation——FDG = fluorodeoxyglucose; FOLFOX = folinic acid, 5-fluorouracil, and oxaliplatin; GLS = global longitudinal strain; LVEF = left ventricular ejection fraction; PET = positron emission tomography. Table 1Left Ventricular Ejection Fraction, Global Longitudinal Strain, and Cancer ManagementTime Before PresentationCancer CourseLVEF (%)GLS (%)22 monthsColorectal cancer diagnosis and left hemicolectomy——20 monthsFOLFOX therapy initiated——19 monthsFOLFOX therapy held, started on metoprolol succinate, losartan, empagliflozin25−12.218 monthsNot on any cancer-directed therapy45−16.416 monthsFDG-avid peritoneal nodule identified on PET——15 monthsPembrolizumab therapy initiated——14 monthsPembrolizumab therapy ongoing40−14.97 monthsPembrolizumab therapy ongoing50−14.71 monthPembrolizumab therapy ongoing60−17.60.5 monthFinal pembrolizumab dose prior to presentation——FDG = fluorodeoxyglucose; FOLFOX = folinic acid, 5-fluorouracil, and oxaliplatin; GLS = global longitudinal strain; LVEF = left ventricular ejection fraction; PET = positron emission tomography. Left Ventricular Ejection Fraction, Global Longitudinal Strain, and Cancer Management FDG = fluorodeoxyglucose; FOLFOX = folinic acid, 5-fluorouracil, and oxaliplatin; GLS = global longitudinal strain; LVEF = left ventricular ejection fraction; PET = positron emission tomography. Differential Diagnosis The differential diagnosis included immune checkpoint inhibitor (ICI) myocarditis, viral lymphocytic myocarditis, acute coronary syndrome (including coronary thrombus in the hypercoagulable state of malignancy), stress cardiomyopathy, and recurrence of nonischemic cardiomyopathy related to prior chemotherapy. Investigations Initial laboratory studies were notable for high-sensitivity troponin I of 8,155 ng/L, lactate 4.9 mmol/L, N-terminal pro–B-type natriuretic peptide 1,693 pg/mL, C-reactive protein 204.7 mg/L, and erythrocyte sedimentation rate 14 mm/h. Notably, respiratory viral panel was negative, and additional studies including thyroid stimulating hormone and creatine phosphokinase were not suggestive of overlap ICI toxicities. Electrocardiogram (ECG) on admission (Figure 1A) showed atrioventricular dissociation, a new left bundle branch block, and ST-segment elevation in leads V1, V2, and aVR. TTE (Video 1) revealed an LVEF of 30%, apical hypokinesis with preserved basal contraction, moderately decreased right ventricular function, and no significant valvular dysfunction. A Swan-Ganz catheter yielded the following hemodynamic parameters: cardiac output 2.5 L/min, cardiac index 1.3 L/min/m2, central venous pressure 18 mm Hg, pulmonary capillary wedge pressure 24 mm Hg, and systemic vascular resistance index 3,157 dyne × s × m2/cm5. Left heart catheterization (Video 2) showed no coronary artery obstruction. A femoral intra-aortic ballon pump was placed for hemodynamic support.Figure 1Electrocardiograms Throughout Hospitalization(A) Electrocardiogram on admission revealing atrioventricular dissociation (red arrows indicate P waves), left bundle-branch block configuration, and ST-segment elevations in leads V1, V2, and AvR. (B) Ventricular tachycardia. (C) High-grade heart block (red arrows indicate P waves). (D) Electrocardiogram before discharge showing normal sinus rhythm and resolution of conduction block. Electrocardiograms Throughout Hospitalization (A) Electrocardiogram on admission revealing atrioventricular dissociation (red arrows indicate P waves), left bundle-branch block configuration, and ST-segment elevations in leads V1, V2, and AvR. (B) Ventricular tachycardia. (C) High-grade heart block (red arrows indicate P waves). (D) Electrocardiogram before discharge showing normal sinus rhythm and resolution of conduction block. Management Given marked troponin elevation, new systolic dysfunction, conduction abnormalities, and cardiac arrest in the absence of obstructive coronary disease, ICI myocarditis was strongly suspected.1 The patient was started on high-dose corticosteroids with methylprednisolone 1,000 mg in addition to inotropes and diuretics. Despite these interventions, his hemodynamics remained undersupported, and lactate levels increased to 12.9 mmol/L. He was subsequently taken for right heart biopsy and peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) cannulation. After VA-ECMO cannulation, he developed sustained runs of ventricular tachycardia (Figure 1B) refractory to antiarrhythmic infusions. Pathology from the endomyocardial biopsy (Figure 2) subsequently confirmed the diagnosis of ICI myocarditis. Given persistent electrical and hemodynamic instability, abatacept (10 mg/kg) was administered in addition to high-dose corticosteroids. On hospital day 3, the patient developed high-grade heart block (Figure 1C) and ventricular asystole requiring transvenous pacing, and therapeutic plasma exchange (TPE) was initiated. He was ultimately treated with 3 doses of methylprednisolone, 3 doses of abatacept (hospital days 2, 3, and 14), and 2 sessions of TPE.Figure 2Right Heart Biopsy HistopathologyHematoxylin and eosin–stained specimen demonstrating lymphocytes infiltrating myocardium. Scale bar = 100 μm. Right Heart Biopsy Histopathology Hematoxylin and eosin–stained specimen demonstrating lymphocytes infiltrating myocardium. Scale bar = 100 μm. Outcomes and Follow-Up Interval TTE on hospital day 5 (Video 3) showed improvement in LVEF (55% to 60%), and the patient was decannulated from VA-ECMO. TTE before discharge (Video 4) showed normal biventricular function, with an LVEF of 60%. His ECG also showed resolution of the conduction abnormalities (Figure 1D). He was transitioned to prednisone 1 mg/kg with a plan for gradual taper. Cardiac magnetic resonance performed 5 weeks after discharge showed normal biventricular function without late gadolinium enhancement as well as normal T1 and T2 mapping. Pembrolizumab was permanently discontinued, and he continues to attend follow-up with his oncologist for surveillance of his peritoneal disease off therapy. Discussion We present a case of late-onset fulminant myocarditis and cardiogenic shock successfully managed with high-dose corticosteroids, abatacept, and TPE while supported on VA-ECMO. Although most cases of ICI myocarditis occur within 3 weeks of treatment initiation,2 this case demonstrates that fulminant disease may occur much later in the treatment course. In the largest early multicenter registry, median time to onset was 34 days (interquartile range: 21-55 days), with 81% of patients presenting within 3 months of starting ICI therapy.3 In contrast, our patient presented with ICI myocarditis 460 days after initiating immunotherapy with pembrolizumab. Notably, only 1 case with a later onset, presenting 987 days after starting immunotherapy, has been described.4 To our knowledge, 460 days is the longest duration between ICI initiation and presentation with fulminant myocarditis that has been successfully treated. The 2022 European Society of Cardiology cardio-oncology guidelines1 allow for the diagnosis of ICI myocarditis by either clinical or pathohistological criteria. Although our patient met clinical criteria for ICI myocarditis (elevated troponin in the absence of coronary disease [Video 2] in addition to new conduction system disease [Figure 1] and a decline in LVEF [Video 1]), the timing of his presentation confounded the diagnosis and prompted endomyocardial biopsy. Pathology ultimately revealed lymphocytic infiltrate (Figure 2), which provided a definitive pathohistological diagnosis. Early diagnosis of ICI myocarditis is critical, as time to corticosteroids positively correlates with major adverse cardiac events.5 The mortality associated with ICI myocarditis ranges from 25% to 50%,6 and European Society of Cardiology guidelines recommend high-dose corticosteroids within the first 24 hours of presentation.1 Our patient received methylprednisolone 1,000 mg within 12 hours of presentation for fulminant ICI myocarditis, which in addition to use of temporary mechanical circulatory support (tMCS) contributed to his positive outcome. The decision to place tMSC was made only after discussion with his outpatient oncologist in conjunction with the heart team, including cardio-oncology, advanced heart failure, interventional cardiology, and critical care medicine. It was ultimately felt that he had a reasonable trajectory from a cancer perspective if he were to recover from the myocarditis. Notably, the tMCS in cancer patients remains underused,7 and this case demonstrates that the presence of cancer or malignancy should not automatically preclude its use in carefully selected patients. Despite an improvement in high-sensitivity troponin levels and hemodynamics after the first dose of methylprednisolone and VA-ECMO support, our patient continued to experience electrical instability with ventricular arrythmias and high-grade heart block (Figures 1B and 1C). The discordance between the high-sensitivity troponin trend and clinical response is notable. Although significantly lower from peak, the troponin levels 24 and 48 hours after the first dose of methylprednisolone remained significantly elevated at 651 and 244 ng/L, respectively, which in the context of electrical instability represented ongoing immunotoxicity not fully treated by corticosteroids and prompted additional immunosuppression. Second-line agents for fulminant myocarditis include CTLA-4 agonists, TPE, CD52 antagonists, mycophenolate, intravenous immunoglobulin, and antithymocyte globulin.8 Abatacept, a CTLA-4-immunoglobulin fusion protein, has shown promise in animal models of ICI myocarditis and early case reports.9 The ATRIUM (abatacept for immune checkpoint inhibitor associated myocarditis) trial is an ongoing phase 3, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept for ICI myocarditis in hospitalized patients.10 Notably, cardiogenic shock, sudden cardiac arrest, and significant tachyarrhythmia are important exclusion criteria, thus our patient does not fall within the study population. There are currently limited supporting data for these second-line agents and no prospective data to guide the choice of individual therapies. The choice of abatacept and TPE in this case was chosen based on availability and past institutional successes with this strategy. Visual SummaryHigh-Sensitivity Troponin I Trend Throughout HospitalizationHs = high sensitivity; IABP = intra-aortic ballon pump; ICI = immune checkpoint inhibitor; LHC = left heart catheterization; RH = right heart; TPE = therapeutic plasma exchange; TVP = transvenous pacer; VA-ECMO = venoarterial extracorporeal membrane oxygenation. High-Sensitivity Troponin I Trend Throughout Hospitalization Hs = high sensitivity; IABP = intra-aortic ballon pump; ICI = immune checkpoint inhibitor; LHC = left heart catheterization; RH = right heart; TPE = therapeutic plasma exchange; TVP = transvenous pacer; VA-ECMO = venoarterial extracorporeal membrane oxygenation. Conclusions ICI myocarditis typically presents early after initiating immunotherapy, but clinicians should remain vigilant for delayed presentations occurring months or even years after therapy initiation. Prompt recognition and early initiation of high-dose corticosteroids with escalation to second-line immunosuppressants and hemodynamic support with tMCS may be lifesaving in fulminant cases. Temporary mechanical circulatory support such as VA-ECMO should be considered in selected patients with fulminant ICI myocarditis event in the setting of active malignancy or metastatic disease. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.Take-Home Messages•ICI myocarditis most commonly presents early after initiation of immunotherapy, but delayed presentation months to even years later can occur and may be fulminant.•Early initiation of high-dose corticosteroids is the cornerstone of therapy, and escalation to second-line immunosuppression and temporary mechanical circulatory support such as VA-ECMO may be lifesaving in carefully selected fulminant cases.•The presence of active malignancy alone should not automatically preclude consideration of temporary mechanical circulatory support where there is a potentially reversible cardiac process and reasonable oncological trajectory. Take-Home Messages •ICI myocarditis most commonly presents early after initiation of immunotherapy, but delayed presentation months to even years later can occur and may be fulminant.•Early initiation of high-dose corticosteroids is the cornerstone of therapy, and escalation to second-line immunosuppression and temporary mechanical circulatory support such as VA-ECMO may be lifesaving in carefully selected fulminant cases.•The presence of active malignancy alone should not automatically preclude consideration of temporary mechanical circulatory support where there is a potentially reversible cardiac process and reasonable oncological trajectory. •ICI myocarditis most commonly presents early after initiation of immunotherapy, but delayed presentation months to even years later can occur and may be fulminant. ICI myocarditis most commonly presents early after initiation of immunotherapy, but delayed presentation months to even years later can occur and may be fulminant. •Early initiation of high-dose corticosteroids is the cornerstone of therapy, and escalation to second-line immunosuppression and temporary mechanical circulatory support such as VA-ECMO may be lifesaving in carefully selected fulminant cases. Early initiation of high-dose corticosteroids is the cornerstone of therapy, and escalation to second-line immunosuppression and temporary mechanical circulatory support such as VA-ECMO may be lifesaving in carefully selected fulminant cases. •The presence of active malignancy alone should not automatically preclude consideration of temporary mechanical circulatory support where there is a potentially reversible cardiac process and reasonable oncological trajectory. The presence of active malignancy alone should not automatically preclude consideration of temporary mechanical circulatory support where there is a potentially reversible cardiac process and reasonable oncological trajectory.